Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Thymoma: early-phase trial registry

2 of 10 indexed Thymoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 2 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Thymoma: 10 US clinical trials tracked, 2 recruiting.

Thymoma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.

Enrollment posture brief

Registry condition thymoma

OPEN 2 | RECR 20% | LATE 0 | EARLY 6 | RANK #1724 | SPON 3

Nearest open-share peer: Acral Lentiginous Melanoma (20% recruiting · 5 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Thymoma (this)20%
Open-enrollment share among volume-matched conditions near Thymoma

Thymoma lists 2 open slots (20% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Thymoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Thymoma is recruiting below its size-band peers.

    2 of 10 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Thymoma research.

    National Cancer Institute (NCI) accounts for 3 of 10 trials (30%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Thymoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 10 trials that report a genuine target (sentinel values excluded). 9 of those (90%) plan for fewer than 100 participants.

  4. Thymoma research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 25

Open and recent trials

10 total, page 1 of 1

RECRUITING 1,000 participants

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

National Cancer Institute (NCI)

NCT01950572

RECRUITING Phase 2 18 participants

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

Georgetown University

NCT06248515

ACTIVE NOT RECRUITING Phase 2 56 participants

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

National Cancer Institute (NCI)

NCT03076554

ACTIVE NOT RECRUITING NA 53 participants

Clinical Investigation of the da Vinci Surgical System

Intuitive Surgical

NCT05682742

ACTIVE NOT RECRUITING NA 40 participants

An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma

M.D. Anderson Cancer Center

NCT03968315

ACTIVE NOT RECRUITING NA 32 participants

SP Thoracic IDE Study

Intuitive Surgical

NCT05150210

ACTIVE NOT RECRUITING Phase 2 18 participants

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

Memorial Sloan Kettering Cancer Center

NCT01025089

COMPLETED Phase 2 56 participants

Sunitinib for Advanced Thymus Cancer Following Earlier Treatment

National Cancer Institute (NCI)

NCT01621568

COMPLETED Phase 2 18 participants

A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer

Indiana University School of Medicine

NCT00369889

COMPLETED Phase 1 6 participants

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Nagla Abdel Karim

NCT03023319

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 5

Named interventions

Most-linked intervention names on Thymoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Robotic-Assisted Surgery Device
1 trials
Robotic-assisted Surgery Device
1 trials
Diaphragm Fluoroscopy Procedure
1 trials
Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide Drug
1 trials
Erlotinib Drug
1 trials
bevacizumab Drug
1 trials
Avelumab Drug
1 trials
Sacituzumab govitecan-hziy Drug
1 trials

US sites by state

Facility locations filed on Thymoma trials. A trial with sites in several states counts in each.

Texas 3 trials
New Jersey 3 trials
Maryland 3 trials
California 3 trials
New York 2 trials
Ohio 1 trials
North Carolina 1 trials
Michigan 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Thymoma page

10 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Thymoma condition card totals 10 registered trials; most-linked intervention Robotic-Assisted Surgery; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.